04 / PRP & Regenerative Injection
One system. Three biologic outputs.
A single FDA 510(k)-cleared benchtop system that processes three distinct biologics from the patient's own blood or marrow: platelet-rich plasma, bone marrow aspirate concentrate, and protein concentrate (A2M and IL-1ra). One 10-minute spin, prepared chairside, with fewer transfer steps than most systems on the market — less mechanical trauma to cells and lower contamination risk.
Platelet-rich plasma. Captures the buffy coat through a simple push method with clear volume markings for reproducible results. Leukocyte concentration is tailorable: the volume of enriched plasma, buffy coat, and white cells can be adjusted to fit the patient and the pathology.
Protein concentrate (A2M). Alpha-2-macroglobulin works by a different mechanism than platelets. Rather than delivering growth factors, it acts as a broad-spectrum protease inhibitor — capturing and neutralizing the matrix metalloproteinases and aggrecanases that degrade cartilage, and downregulating IL-1 and NF-κB inflammatory signaling. In a rat model of osteoarthritis, supplemental intra-articular A2M was identified as a master inhibitor of cartilage-degrading factors and attenuated the progression of post-traumatic OA. For a degenerative joint, that means protecting the matrix rather than only stimulating repair.
83%
Platelet capture rate
10x
Platelet concentration over baseline
10.8B
Platelets per dose, avg.
Mechanism: single-spin concentration · PRP, BMC, and A2M/IL-1ra from one FDA 510(k) system
